The latest price target for Bio-Rad Laboratories (NYSE:BIO) was reported by RBC Capital on December 9, 2024. The analyst firm set a price target for $481.00 expecting BIO to rise to within 12 months (a possible 46.88% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Bio-Rad Laboratories (NYSE:BIO) was provided by RBC Capital, and Bio-Rad Laboratories maintained their outperform rating.

The last upgrade for Bio-Rad Laboratories Inc happened on October 1, 2024 when Citigroup raised their price target to $400. Citigroup previously had a neutral for Bio-Rad Laboratories Inc.

The last downgrade for Bio-Rad Laboratories Inc happened on April 3, 2024 when Citigroup changed their price target from $400 to $365 for Bio-Rad Laboratories Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bio-Rad Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bio-Rad Laboratories was filed on December 9, 2024 so you should expect the next rating to be made available sometime around December 9, 2025.

While ratings are subjective and will change, the latest Bio-Rad Laboratories (BIO) rating was a maintained with a price target of $369.00 to $481.00. The current price Bio-Rad Laboratories (BIO) is trading at is $327.47, which is out of the analyst’s predicted range.